颅骨剂量学对非小细胞肺癌脑转移患者颅脑放疗联合免疫治疗急性血液学毒性的影响
本研究回顾性纳入191例2018年6月至2023年4月接受颅脑放疗联合免疫治疗的非小细胞肺癌脑转移患者,分析颅骨剂量参数与≥3级血液学毒性的关联。结果显示颅骨剂量越高,严重血液学毒性风险越高、放疗后绝对淋巴细胞计数越低、免疫治疗应答率越低,提示颅骨剂量约束可能减轻毒性并保护淋巴细胞。
要点
- 颅骨DmeanEQD2及V5-V20EQD2与≥3级血液学毒性显著相关。
- 颅骨DmeanEQD2≥32.2 Gy等阈值以上患者严重血液学毒性风险增加逾两倍。
- 阈值以上患者放疗后绝对淋巴细胞计数更低且免疫治疗应答率更低。
核心结论
- 较高的颅骨放疗剂量显著增加接受颅脑放疗联合免疫治疗的非小细胞肺癌脑转移患者的严重血液学毒性。
- 引入颅骨剂量约束可能减轻血液学毒性、保护淋巴细胞并增强免疫治疗疗效,尚需前瞻性研究验证。
研究设计与样本
- 回顾性研究连续纳入191例2018年6月至2023年4月接受颅脑放疗联合免疫治疗的非小细胞肺癌脑转移患者。
- 根据病灶特征选择立体定向放疗或全脑放疗,所有剂量转换为等效2 Gy分次(EQD2)。
- 血液学毒性采用美国国家癌症研究所不良事件通用术语标准5.0版分级。
- 采用逻辑回归分析颅骨剂量参数(DmeanEQD2、V5EQD2-V50EQD2)与≥3级血液学毒性的关联,并建立正常组织并发症概率模型和受试者工作特征分析确定最佳截断值。
主要发现
- ≥3级血液学毒性发生率为18.8%(36/191),最常见为中性粒细胞减少(18.9%)、白细胞减少(15.2%)和淋巴细胞减少(15.7%)。
- 多因素分析校正年龄及其他协变量后,≥3级血液学毒性与DmeanEQD2及V5EQD2-V20EQD2显著相关(均P < .05)。
- 正常组织并发症概率模型预测≥3级血液学毒性50%概率的阈值为DmeanEQD2=41.3 Gy、V5EQD2=94.6%、V10EQD2=86.0%、V20EQD2=77.0%。
- 受试者工作特征分析确定≥3级血液学毒性最佳截断值为DmeanEQD2≥32.2 Gy、V5EQD2≥82.0%、V10EQD2≥64.7%、V20EQD2≥53.4%。
- 高于上述阈值的患者≥3级血液学毒性风险增加逾两倍,放疗后绝对淋巴细胞计数显著更低,免疫治疗应答率降低(均P < .05),且放疗后绝对淋巴细胞计数越高预测应答越好。
关键数值与推荐
- ≥3级血液学毒性最佳截断值:DmeanEQD2≥32.2 Gy、V5EQD2≥82.0%、V10EQD2≥64.7%、V20EQD2≥53.4%。
- 正常组织并发症概率模型50%≥3级血液学毒性概率阈值:DmeanEQD2=41.3 Gy、V5EQD2=94.6%、V10EQD2=86.0%、V20EQD2=77.0%。
临床怎么用
- 在非小细胞肺癌脑转移患者接受颅脑放疗联合免疫治疗时,可考虑评估颅骨剂量参数以识别严重血液学毒性高风险患者。
- 参考DmeanEQD2≥32.2 Gy、V5EQD2≥82.0%、V10EQD2≥64.7%、V20EQD2≥53.4%等截断值优化颅骨剂量约束,可能减轻血液学毒性并保护淋巴细胞。
局限性
- 本研究为回顾性研究,结果需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Brain radiation therapy (RT) combined with immunotherapy is standard for patients with non-small cell lung cancer (NSCLC) with brain metastases. However, RT-induced hematologic toxicities (HTs) can cause treatment interruption and lymphopenia, potentially impairing immunotherapy efficacy. Because the skull bone marrow has recently been identified as a key hematopoietic site, this study evaluated the impact of skull RT dose on HTs in patients with NSCLC undergoing cranial RT and immunotherapy. METHODS AND MATERIALS: This retrospective study consecutively included 191 patients with NSCLC with brain metastases treated between June 2018 and April 2023. Stereotactic RT or whole-brain RT was selected based on lesion characteristics. All doses were converted to equivalent 2-Gy fractions (EQD2). HTs were graded using the National Cancer Institute Common Toxicity Criteria for Adverse Events version 5.0. Skull dosimetric parameters (DmeanEQD2, V5EQD2 - V50EQD2) were analyzed for associations with grade ≥ 3 HTs (HT3+) using logistic regression. Normal tissue complication probability models and optimal cutoff thresholds were derived using logistic and receiver operating characteristic analyses. Based on these cutoffs, post-RT absolute lymphocyte count (ALC) and immunotherapy response rates were assessed in stratified groups. RESULTS: HT3+ occurred in 18.8% (36/191) of patients, with neutropenia (18.9%), leukopenia (15.2%), and lymphopenia (15.7%) being most frequent. Multivariate analysis, adjusting for age and other covariates, revealed significant associations between HT3+ and DmeanEQD2 as well as V5EQD2 -V20EQD2 (all P < .05). The normal tissue complication probability models predicted a 50% probability of HT3+ at the following thresholds: DmeanEQD2 = 41.3 Gy, V5EQD2 = 94.6%, V10EQD2 = 86.0%, and V20EQD2 = 77.0%. Receiver operating characteristic analysis identified optimal HT3+ cutoffs of DmeanEQD2≥ 32.2 Gy, V5EQD2≥ 82.0%, V10EQD2≥ 64.7%, and V20EQD2≥ 53.4%. Patients above these thresholds had over twice the HT3+ risk, significantly lower post-RT ALC, and reduced immunotherapy response rates (all P < .05), with higher post-RT ALC predicted better response. CONCLUSIONS: Higher skull radiation doses significantly increase severe HTs in patients with NSCLC receiving cranial RT and immunotherapy. Incorporating skull dose constraints may mitigate HTs, preserve lymphocytes, and enhance immunotherapy efficacy, warranting validation in prospective studies.
引用
- Ma J, Yu H, Zhang X, et al. Skull Dosimetry for Mitigating Acute Hematologic Toxicity in Patients With Non-small Cell Lung Cancer With Brain Metastases Undergoing Cranial Radiation Therapy and Immunotherapy. Int J Radiat Oncol Biol Phys. 2025. PMID: 41453453. doi:10.1016/j.ijrobp.2025.12.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。